<DOC>
	<DOCNO>NCT01818999</DOCNO>
	<brief_summary>This study do find effect Stereotactic body radiation therapy ( SBRT ) combination Ixabepilone woman triple negative metastatic breast cancer .</brief_summary>
	<brief_title>Ixabepilone SBRT For Metastatic Breast Cancer</brief_title>
	<detailed_description>Ixabepilone FDA approve drug treatment metastatic locally advanced breast cancer failure chemotherapy . SBRT treatment method deliver high dose radiation target , utilize either single dose small number treatment high degree precision within body . The combination Ixabepilone SBRT approve treatment time .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>1 . Biopsy proven triple negative invasive ductal lobular metastatic breast cancer . Tumor estrogen , progesterone , HER2 ( test IHC FISH ) negative disease . ( ER define &lt; /=1 % IHC , PR define &lt; /=1 % IHC , HER2 IHC 1+ . If HER2 result IHC 2+ ( equivocal ) , tumor must confirm HER2 FISH . 2 . Age ≥ 18 year . 3 . Patients must start Ixabepilone treatment 5 week prior initiation SBRT treatment . 4 . Patients 6 site active extracranial disease ( &lt; /=3 liver = one site &lt; /=3 lung= one site ) identify CT scan , PET/CT , within 8 week prior initiation SBRT ( 2 contiguous vertebral metastasis consider single site disease ) . Maximum number lesion treat deem feasible per treat radiation oncologist ; ie : A patient 4 right axillary lymph node , L1L2 bone metastasis , 3 lung lesion , 1 leave lung lesion , 2 liver lesion , T2T3 bone metastasis would define 6 site disease . Criteria define lesion location metastasis require local treatment one sit SBRT lesion clinically felt viable ; define enlarge CT/MRI persistent FDG avidity ( Either SUV &gt; 3 increase SUV &gt; 20 % 6 month interval ) . 5 . Patients skin nodule , skin invasion , skin ulceration eligible , treatment conventional radiation ( discretion radiation oncologist ) surgery plan . SBRT skin nodule advise risk skin necrosis . 6. . Patients must failure anthracycline , taxane capecitabine per FDA approve criterion . 7 . Performance status ECOG 0,1 , 2 . 8 . Adequate organ marrow function define : leukocyte ≥ 3,000/mcL absolute neutrophil count ≥ 1,500/mcL platelet ≥ 100,000/mcl total bilirubin within normal institutional limit AST ( SGOT ) /ALT ( SPGT ) ≤ 2.5 X institutional upper limit normal creatinine within normal institutional limit 9 . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation , 90 day follow completion therapy . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . 9.1 A female childbearing potential woman ( regardless sexual orientation , undergone tubal ligation , remain celibate choice ) meet follow criterion : Has undergone hysterectomy bilateral oophorectomy ; Has naturally postmenopausal least 12 consecutive month ( i.e. , menses time precede 12 consecutive month ) . 10 . Patients would receive SBRT lung tumor know must document forced expiratory volume 1 second ( FEV1 ) &gt; /=30 % . 11 . Must CT C/A/P , PET/CT scan within 8 week enrollment . 12 . Ability understand willingness sign write informed consent 1 . Patients may actively receive investigational agent . 2 . Patients untreated brain metastasis ( patient whole brain radiation stereotactic radiation brain prior enrollment ) . 3 . Patients leptomeningeal disease . 4 . History allergic reaction attribute compound similar chemical biologic composition Agent ( ) use study . Patients history severe reaction Cremephor EL derivative ( polyoxyethylated castor oil ) ineligible Ixabepilone contraindicate patient 5 . Because tolerance dose SBRT gastrointestinal tract establish , patient metastatic disease invade esophagus , stomach , intestine , mesenteric lymph node eligible . 6 . Patients 6 discrete extracranial site . 7 . Treatment carcinoma within last 5 year , except cure nonmelanoma skin treat insitu cancer . 8 . Patients must pregnant nursing due potential congenital abnormality potential regimen harm nursing infant . 9 . Patients must concomitant CYP3A4 inhibitor inducer ( see section 4.3 ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>METASTATIC BREAST CANCER</keyword>
</DOC>